ARKG ARK Genomic Revolution ETF
- 24.780
- +0.510+2.10%
Here's the Major Earnings Before the Open Tomorrow
How Is The Market Feeling About Natera?
CareDx Non-GAAP EPS of $0.14 Beats by $0.13, Revenue of $82.88M Beats by $2.17M
CareDx Raises FY24 Revenue Guidance From $320M - $328M To $327M - $331M, Est $325.969M
Editas Downgraded to Market Perform by Raymond James
Peering Into Recursion Pharmaceuticals's Recent Short Interest
10 Health Care Stocks Moving In Monday's Pre-Market Session
Earnings Week Ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and More
CareDx Q3 2024 Earnings Preview
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
TechBio Startup Cure51 Selects 10x Genomics Visium HD For New Drug Discovery Initiative; Cure51 Plans To Analyze More Than 1,000 Tumor Samples From Exceptional Cancer Survivors
Bernstein Maintains Outperform on Natera, Raises Price Target to $135
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $20
12 Health Care Stocks Moving In Tuesday's After-Market Session
10x Genomics Cuts FY24 Revenue Guidance From $640M-$5660M To $595M-$605M Vs. $636.595M Est
Natera Shares Are Trading Higher After Canaccord Genuity Maintained a Buy Rating on the Stock and Raised Its Price Target From $145 to $150.
Here Are the Major Earnings After the Close Today
10x Genomics Q3 2024 Earnings Preview
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus